Aditya Birla (ABSL) Pharma & Healthcare Fund

⚖️ Sahifund Review – Aditya Birla Sun Life Pharma & Healthcare Fund ✔

PLUS:
✓ Backed by the strong healthcare research capability and long-term equity management experience of Aditya Birla Sun Life Mutual Fund.
✓ Strong 3-year CAGR of 24.41% reflects solid participation in the healthcare and pharma sector rally.
✓ Fund has delivered healthy long-term wealth creation with return since launch above 20%.
✓ Balanced exposure across large-cap, mid-cap and small-cap healthcare companies enhances diversification potential.
✓ Moderate turnover ratio of 26% reflects relatively stable portfolio management discipline.
✓ Healthcare remains a structurally important long-term theme supported by rising healthcare spending and exports.
✓ Suitable mainly for aggressive SIP investors seeking dedicated healthcare sector exposure with long investment horizons.

MINUS:
⚖️ 1-year and 5-year returns trail several leading pharma fund peers like ICICI Prudential and UTI Healthcare Fund.
⚖️ Portfolio concentration remains extremely high with top 3 sectors accounting for nearly 98% exposure.
⚖️ Portfolio P/E of 36.66 suggests relatively expensive valuations within healthcare and pharma businesses.
⚖️ Small-cap allocation above 37% increases volatility risk during market corrections and regulatory uncertainty.
⚖️ Pharma and healthcare funds can underperform sharply during non-defensive and cyclical market rallies.
⚖️ Expense ratio of 1.01% is reasonable but still higher than certain competing healthcare-focused schemes.
⚖️ Sector-specific investing is unsuitable as a core portfolio allocation for conservative long-term investors.

Sahifund View (Decisive Line):
Aditya Birla Sun Life Pharma & Healthcare Fund can work as a tactical SIP allocation for healthcare believers, but diversified flexi-cap and large-cap funds remain safer long-term wealth creation vehicles for most investors.